Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.
about
Genetics and genomics of radiotherapy toxicity: towards predictionAnti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.Targeted therapy in head and neck cancer.The effect of lentivirus-mediated expression of tumor necrosis factor related apoptosis-inducing ligand and shRNA against Bcl-2 on the growth of lymphoma cells.
P2860
Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Radioimmunotherapy for the tre ...... tatus and future applications.
@en
Radioimmunotherapy for the tre ...... tatus and future applications.
@nl
type
label
Radioimmunotherapy for the tre ...... tatus and future applications.
@en
Radioimmunotherapy for the tre ...... tatus and future applications.
@nl
prefLabel
Radioimmunotherapy for the tre ...... tatus and future applications.
@en
Radioimmunotherapy for the tre ...... tatus and future applications.
@nl
P2860
P1433
P1476
Radioimmunotherapy for the tre ...... status and future applications
@en
P2093
Jane N Winter
Sairah Ahmed
P2860
P304
P356
10.3109/10428191003793366
P577
2010-07-01T00:00:00Z